此外，和铂医药近期公告，公司全资附属公司诺纳生物，与Candid已就开发下一代T细胞衔接器达成一项研究合作及授权协议。根据协议条款，诺纳生物有权获得首付款和潜在里程碑付款最高达3.2亿美元。Candid将负责产品的所有后续开发工作。HBM HOLDINGS-B (02142) has risen over 6% again, as of the time of writing, up 2.15%, reported at 1.9 Hong Kong dollars, with a trading volume of 2.4537 million Hong Kong dollars.
According to Zhitong Finance APP, HBM HOLDINGS-B (02142) has risen over 6% again, as of the time of writing, up 2.15%, priced at 1.9 Hong Kong dollars, with a transaction volume of 2.4537 million Hong Kong dollars.
In terms of news, HBM HOLDINGS announced that based on the general authorization for share repurchases approved by the company's Shareholder at the annual general meeting on June 6, 2024, and any general authorization for share repurchase that future Shareholders may approve at the company's periodic general meetings, it intends to repurchase company shares on the open market, with a value not exceeding 40 million Hong Kong dollars.
In addition, HBM HOLDINGS recently announced that its wholly-owned subsidiary, Nuna Bio, has reached a research cooperation and licensing agreement with Candid to develop the next generation T cell connector. According to the terms of the agreement, Nuna Bio is entitled to receive an upfront payment and potential milestone payments of up to 0.32 billion US dollars. Candid will be responsible for all subsequent development work on the product.
